ID   RMUG-S
AC   CVCL_3158
SY   RMUGS
DR   CLO; CLO_0037297
DR   EFO; EFO_0006747
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03471004
DR   BioSample; SAMN10987616
DR   CCLE; RMUGS_OVARY
DR   Cell_Model_Passport; SIDM01347
DR   CGH-DB; 347-2
DR   CGH-DB; 350-3
DR   Cosmic; 1305332
DR   Cosmic; 2429304
DR   DepMap; ACH-000701
DR   GEO; GSM659404
DR   GEO; GSM887545
DR   GEO; GSM888628
DR   IARC_TP53; 28251
DR   JCRB; IFO50320
DR   LiGeA; CCLE_579
DR   PharmacoDB; RMUGS_1321_2019
DR   Wikidata; Q54950735
RX   CelloPub=CLPUB00481;
RX   PubMed=2083224;
RX   PubMed=17671176;
RX   PubMed=19154404;
RX   PubMed=22246397;
RX   PubMed=22460905;
RX   PubMed=23839242;
RX   PubMed=25485619;
RX   PubMed=25984343;
RX   PubMed=28196595;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 43 hours (PubMed=2083224); 75 hours (PubMed=25984343); ~25 hours (lot 03162009), ~36 hours (lot 02242017) (JCRB).
CC   Sequence variation: Homozygous for TP53 p.Ala347Val (c.1040C>T) (CCLE).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.94%; Native American=0.79%; East Asian, North=40.77%; East Asian, South=53.64%; South Asian=0%; European, North=0%; European, South=3.86% (PubMed=30894373).
CC   Misspelling: RUMG-S; In CGH-DB 347-2 and CGH-DB 350-3.
ST   Source(s): JCRB; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10,11
ST   D16S539: 10,11
ST   D18S51: 13
ST   D19S433: 12,14.2
ST   D21S11: 30
ST   D2S1338: 17,25
ST   D3S1358: 14
ST   D5S818: 10,14
ST   D7S820: 12
ST   D8S1179: 11
ST   FGA: 19,24
ST   Penta D: 13
ST   Penta E: 5,18
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 14,16
DI   NCIt; C4026; Ovarian mucinous cystadenocarcinoma
DI   ORDO; Orphanet_398961; Mucinous adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 24
//
RX   CelloPub=CLPUB00481;
RA   Kuno H., Yoshida T.;
RT   "Detection of human papillomavirus types 16, 18, and 33 in cell lines
RT   derived from human genital organs by polymerase chain reaction.";
RL   Res. Commun. Inst. Ferment. Osaka 18:6-12(1997).
//
RX   PubMed=2083224;
RA   Sakayori M., Nozawa S., Udagawa Y., Chin K., Lee S.G., Sakuma T.,
RA   Iizuka R., Wada Y., Yoshida S., Takeda Y.;
RT   "Biological properties of two newly established cell lines (RMUG-S,
RT   RMUG-L) from a human ovarian mucinous cystadenocarcinoma.";
RL   Hum. Cell 3:52-56(1990).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//
RX   PubMed=19154404; DOI=10.1111/j.1349-7006.2008.01065.x;
RA   Sato S., Itamochi H., Kigawa J., Oishi T., Shimada M., Sato S.,
RA   Naniwa J., Uegaki K., Nonaka M., Terakawa N.;
RT   "Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an
RT   effective regimen for mucinous adenocarcinoma of the ovary: a
RT   potential treatment strategy.";
RL   Cancer Sci. 100:546-551(2009).
//
RX   PubMed=22246397; DOI=10.3892/or.2012.1626;
RA   Sato N., Saga Y., Mizukami H., Wang D., Fujiwara H., Takei Y.,
RA   Machida S., Ozawa K., Suzuki M.;
RT   "Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor
RT   cells lacking KRAS gene mutations.";
RL   Oncol. Rep. 27:1336-1340(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126-2126(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R., Easwaran H., Baylin S.B., Slamon D.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402(2020).
//